EMD 302
Alternative Names: EMD-302Latest Information Update: 16 Jun 2023
At a glance
- Originator Emendo biotherapeutics
- Class Antihyperlipidaemics; Gene therapies; Skin disorder therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Hyperlipidaemia
Most Recent Events
- 16 Jun 2023 Early research in Hyperlipidaemia in USA (Parenteral) (Emendo biotherapeutics pipeline, June 2023)
- 19 Oct 2022 Preclinical trials in Inborn error metabolic disorders in USA (Parenteral) (Emendo biotherapeutics pipeline, October 2022)
- 06 Jan 2021 EMD 302 is available for licensing as of 16 Dec 2021. ttps://emendobio.com/our-technology/,